Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01740791

Enrollment

103

Registered

2012-12-04

Start date

2012-11-06

Completion date

2014-01-24

Last updated

2020-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C Virus

Keywords

Hepatitis C, HCV, Genotype 1, Genotype 2, Genotype 3, Genotype 4, Genotype 5, Genotype 6, Liver Disease

Brief summary

The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.

Interventions

DRUGVelpatasvir

Tablets administered orally

DRUGPlacebo

Tablets administered orally

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Key Inclusion Criteria: * HCV treatment-naive adult participants (18-65 years of age) with chronic HCV infection and plasma HCV RNA ≥ 5 log10 IU/mL at screening * Agree to use protocol defined precautions against pregnancy Key

Exclusion criteria

* Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson's disease, α1 antitrypsin deficiency, cholangitis) * Evidence of cirrhosis * Evidence of current drug abuse * Screening laboratory results outside the protocol specified requirements Note: Other protocol defined Inclusion/

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants Experiencing Treatment Emergent Adverse Events	First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)	Treatment-emergent adverse events were defined as any new or worsening adverse event that began on or after the date of the first dose of study drug until the Day 17 study visit date + 2 (Day 19 if Day 17 visit missing).
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)	A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline at any postbaseline visit up to the Day 17 visit date + 2 days (or Day 19 if Day 17 visit was missing). The criteria used to grade laboratory results were as follows: Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe). Graded laboratory abnormalities were defined using the grading scheme defined in protocol (Gilead Sciences, Inc. Grading Scale for Severity of Adverse Events and Laboratory Abnormalities) for analysis purpose.
Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Baseline; Days 4, 5, 6, 7, 8, 10, and 17	Participants who were genotyped incorrectly but received appropriate treatment for that genotype were included in that treatment group for the efficacy analysis. Data were summarized by treatment and placebo.

Secondary

Measure	Time frame	Description
Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Days 4, 5, 6, 7, and 8	The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 25 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay.
Plasma HCV RNA Levels by Treatment and IL28B Genotype	Days 4, 5, 6, 7, 8, 10, and 17	—
Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1	AUCinf is defined as the concentration of drug extrapolated to infinite time.
PK Parameter of Velpatasvir: Ctau	0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3	Ctau is defined as the observed drug concentration at the end of the dosing interval.
PK Parameter of Velpatasvir: Cmax	0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose.	Cmax is defined as the maximum observed plasma concentration of drug.
PK Parameter of Velpatasvir: CL/F	0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose	CL/F is defined as the apparent oral clearance following administration of the drug.
Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	First dose date up to Day 17	The full-length NS5A coding region was analyzed pretreatment (baseline) by deep sequencing using MiSeq for all 70 participants who received velpatasvir and for 8 of 17 participants who received placebo prior to and up to 2 weeks (Day 17) after dosing with velpatasvir. Participants were categorized by velpatasvir dose/HCV genotype and presence or absence of NS5A RAVs.
PK Parameter of Velpatasvir: AUCtau	0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3	AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).
Absolute HCV RNA Level	Baseline; Days 4, 5, 6, 7, 8, 10, and 17	—
Number of Participants Achieving Reductions From Baseline in HCV RNA	Baseline; Days 4, 5, 6, 7, 8, 10, and 17	Categorical declines from baseline were summarized by the number of participants with a \< 1, ≥ 1 to \< 2, ≥ 2 to \< 3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline by treatment (velpatasvir dose/HCV genotype) and placebo at each collection time point through Day 17.

Countries

Puerto Rico, United States

Participant flow

Recruitment details

Participants were enrolled at study sites in United States. The first participant was screened on 06 November 2012. The last study visit occurred on 24 January 2014.

Pre-assignment details

163 participants were screened. Participants were not enrolled in 'Velpatasvir up to 400 mg genotype (GT) 2' group.

Participants by arm

Arm	Count
Placebo Participants with HCV infection received placebo once daily for 3 days under fasted conditions.	17
Velpatasvir 5 mg Participants with HCV infection received velpatasvir 5 mg once daily for 3 days under fasted conditions.	4
Velpatasvir 25 mg Participants with HCV infection received velpatasvir 25 mg once daily for 3 days under fasted conditions.	15
Velpatasvir 50 mg Participants with HCV infection received velpatasvir 50 mg once daily for 3 days under fasted conditions.	12
Velpatasvir 100 mg Participants with HCV infection received velpatasvir 100 mg once daily for 3 days under fasted conditions.	8
Velpatasvir 150 mg Participants with HCV infection received velpatasvir 150 mg once daily for 3 days under fasted conditions.	31
Total	87

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005
Overall Study	Adverse Event	0	0	0	0	0	1
Overall Study	Investigator's discretion	1	0	1	0	0	1
Overall Study	Lost to Follow-up	2	0	2	3	2	3
Overall Study	Randomized but never treated	5	3	2	2	1	3
Overall Study	Withdrew Consent	4	0	1	2	0	3

Baseline characteristics

Characteristic	Placebo	Velpatasvir 5 mg	Velpatasvir 25 mg	Velpatasvir 50 mg	Velpatasvir 100 mg	Velpatasvir 150 mg	Total
Age, Continuous	46.6 years STANDARD_DEVIATION 11.46	44.8 years STANDARD_DEVIATION 15.65	45.1 years STANDARD_DEVIATION 11.56	46.9 years STANDARD_DEVIATION 10.13	47.0 years STANDARD_DEVIATION 8.4	49.2 years STANDARD_DEVIATION 9.12	47.3 years STANDARD_DEVIATION 10.26
HCV Genotype 1a	10 Participants	4 Participants	8 Participants	8 Participants	8 Participants	7 Participants	45 Participants
HCV Genotype 1b	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	8 Participants	10 Participants
HCV Genotype 2b	2 Participants	0 Participants	0 Participants	0 Participants	0 Participants	8 Participants	10 Participants
HCV Genotype 3	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
HCV Genotype 3a	3 Participants	0 Participants	6 Participants	4 Participants	0 Participants	6 Participants	19 Participants
HCV Genotype 4	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
HCV Genotype 4a/4c/4d	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants	1 Participants
HCV RNA (log10 IU/mL)	6.52 log10 IU/mL STANDARD_DEVIATION 0.517	6.64 log10 IU/mL STANDARD_DEVIATION 0.312	6.32 log10 IU/mL STANDARD_DEVIATION 0.826	6.39 log10 IU/mL STANDARD_DEVIATION 0.558	6.46 log10 IU/mL STANDARD_DEVIATION 0.479	6.41 log10 IU/mL STANDARD_DEVIATION 0.603	6.43 log10 IU/mL STANDARD_DEVIATION 0.597
IL28B Genotype C/C	7 Participants	2 Participants	5 Participants	5 Participants	2 Participants	5 Participants	26 Participants
IL28B Genotype C/T	5 Participants	2 Participants	8 Participants	5 Participants	6 Participants	18 Participants	44 Participants
IL28B Genotype T/T	5 Participants	0 Participants	2 Participants	2 Participants	0 Participants	8 Participants	17 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	1 Participants
Race/Ethnicity, Customized Black or African American	6 Participants	0 Participants	5 Participants	4 Participants	2 Participants	10 Participants	27 Participants
Race/Ethnicity, Customized Hispanic or Latino	8 Participants	1 Participants	3 Participants	6 Participants	2 Participants	8 Participants	28 Participants
Race/Ethnicity, Customized Not Hispanic or Latino	9 Participants	3 Participants	12 Participants	6 Participants	6 Participants	23 Participants	59 Participants
Race/Ethnicity, Customized White	11 Participants	4 Participants	10 Participants	7 Participants	6 Participants	21 Participants	59 Participants
Sex: Female, Male Female	3 Participants	1 Participants	3 Participants	2 Participants	2 Participants	8 Participants	19 Participants
Sex: Female, Male Male	14 Participants	3 Participants	12 Participants	10 Participants	6 Participants	23 Participants	68 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk
deaths Total, all-cause mortality	0 / 17	0 / 4	0 / 15	0 / 12	0 / 8	0 / 31
other Total, other adverse events	3 / 17	1 / 4	4 / 15	1 / 12	3 / 8	6 / 31
serious Total, serious adverse events	0 / 17	0 / 4	0 / 15	0 / 12	0 / 8	0 / 31

Outcome results

Primary

Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline

Participants who were genotyped incorrectly but received appropriate treatment for that genotype were included in that treatment group for the efficacy analysis. Data were summarized by treatment and placebo.

Time frame: Baseline; Days 4, 5, 6, 7, 8, 10, and 17

Population: Participants in the Efficacy Analysis Set (all randomized participants with appropriate genotype who received at least one dose of the study drug (velpatasvir or placebo) and with at least one on-treatment HCV RNA assessment) with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	0.142 log10 IU/mL	Standard Deviation 0.3813
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	0.027 log10 IU/mL	Standard Deviation 0.274
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-0.037 log10 IU/mL	Standard Deviation 0.2119
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-0.005 log10 IU/mL	Standard Deviation 0.3343
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-0.003 log10 IU/mL	Standard Deviation 0.1923
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-0.018 log10 IU/mL	Standard Deviation 0.2346
Placebo	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.025 log10 IU/mL	Standard Deviation 0.2719
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-1.998 log10 IU/mL	Standard Deviation 0.8305
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-1.031 log10 IU/mL	Standard Deviation 0.6112
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.104 log10 IU/mL	Standard Deviation 0.7348
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-0.679 log10 IU/mL	Standard Deviation 0.4352
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-1.244 log10 IU/mL	Standard Deviation 0.6135
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.135 log10 IU/mL	Standard Deviation 0.3747
Velpatasvir 5 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-0.941 log10 IU/mL	Standard Deviation 0.5345
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.223 log10 IU/mL	Standard Deviation 0.4236
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-2.074 log10 IU/mL	Standard Deviation 0.7701
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-3.538 log10 IU/mL	Standard Deviation 0.7566
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.638 log10 IU/mL	Standard Deviation 0.435
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-1.304 log10 IU/mL	Standard Deviation 1.0374
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-3.140 log10 IU/mL	Standard Deviation 0.9786
Velpatasvir 25 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-2.424 log10 IU/mL	Standard Deviation 0.7292
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-2.184 log10 IU/mL	Standard Deviation 1.5527
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.702 log10 IU/mL	Standard Deviation 1.6152
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.338 log10 IU/mL	Standard Deviation 1.3088
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-3.123 log10 IU/mL	Standard Deviation 1.5009
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-1.110 log10 IU/mL	Standard Deviation 1.3584
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-1.472 log10 IU/mL	Standard Deviation 1.4315
Velpatasvir 50 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-2.704 log10 IU/mL	Standard Deviation 1.51
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-1.143 log10 IU/mL	Standard Deviation 1.2137
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-2.273 log10 IU/mL	Standard Deviation 1.1753
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-2.713 log10 IU/mL	Standard Deviation 1.1206
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.801 log10 IU/mL	Standard Deviation 0.7679
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.780 log10 IU/mL	Standard Deviation 0.9987
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.154 log10 IU/mL	Standard Deviation 1.0089
Velpatasvir 100 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-3.060 log10 IU/mL	Standard Deviation 1.1098
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-3.221 log10 IU/mL	Standard Deviation 1.2323
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.648 log10 IU/mL	Standard Deviation 0.927
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-2.032 log10 IU/mL	Standard Deviation 1.4388
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-3.636 log10 IU/mL	Standard Deviation 1.0023
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.879 log10 IU/mL	Standard Deviation 0.9231
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-2.544 log10 IU/mL	Standard Deviation 1.546
Velpatasvir 150 mg	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-2.481 log10 IU/mL	Standard Deviation 1.3542
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-4.205 log10 IU/mL	Standard Deviation 0.4393
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.848 log10 IU/mL	Standard Deviation 0.4834
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-3.955 log10 IU/mL	Standard Deviation 0.3519
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-4.021 log10 IU/mL	Standard Deviation 0.3681
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-4.026 log10 IU/mL	Standard Deviation 0.3155
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-3.348 log10 IU/mL	Standard Deviation 0.6201
Velpatasvir 150 mg (GT 1b)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-1.532 log10 IU/mL	Standard Deviation 1.2059
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-2.918 log10 IU/mL	Standard Deviation 1.1566
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-3.850 log10 IU/mL	Standard Deviation 0.963
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.886 log10 IU/mL	Standard Deviation 1.319
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-4.044 log10 IU/mL	Standard Deviation 0.3671
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-3.559 log10 IU/mL	Standard Deviation 0.9866
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-4.109 log10 IU/mL	Standard Deviation 0.6408
Velpatasvir 150 mg (GT 2)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-4.148 log10 IU/mL	Standard Deviation 0.5841
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-2.796 log10 IU/mL	Standard Deviation 1.4313
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-2.617 log10 IU/mL	Standard Deviation 1.3034
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-0.844 log10 IU/mL	Standard Deviation 0.6967
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-1.586 log10 IU/mL	Standard Deviation 1.071
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.025 log10 IU/mL	Standard Deviation 1.1864
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.672 log10 IU/mL	Standard Deviation 0.5003
Velpatasvir 25 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-2.193 log10 IU/mL	Standard Deviation 1.106
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-1.742 log10 IU/mL	Standard Deviation 1.3842
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-1.737 log10 IU/mL	Standard Deviation 1.3854
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.085 log10 IU/mL	Standard Deviation 0.691
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.542 log10 IU/mL	Standard Deviation 1.0593
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-2.130 log10 IU/mL	Standard Deviation 1.4385
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-1.051 log10 IU/mL	Standard Deviation 1.4338
Velpatasvir 50 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-2.382 log10 IU/mL	Standard Deviation 1.5028
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-2.259 log10 IU/mL	Standard Deviation 1.1488
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-2.834 log10 IU/mL	Standard Deviation 0.7608
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.062 log10 IU/mL	Standard Deviation 1.5998
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-1.869 log10 IU/mL	Standard Deviation 1.327
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-1.380 log10 IU/mL	Standard Deviation 1.6686
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.225 log10 IU/mL	Standard Deviation 0.421
Velpatasvir 150 mg (GT 3)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-1.198 log10 IU/mL	Standard Deviation 1.0991
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 7	-1.892 log10 IU/mL	Standard Deviation 1.0143
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 10	-0.494 log10 IU/mL	Standard Deviation 0.8933
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 4	-3.269 log10 IU/mL	Standard Deviation 0.608
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 6	-2.243 log10 IU/mL	Standard Deviation 0.5919
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 5	-2.827 log10 IU/mL	Standard Deviation 0.5506
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 8	-1.478 log10 IU/mL	Standard Deviation 1.1542
Velpatasvir 150 mg (GT 4)	Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline	Change at Day 17	-0.351 log10 IU/mL	Standard Deviation 0.5914

Primary

Percentage of Participants Experiencing Treatment Emergent Adverse Events

Treatment-emergent adverse events were defined as any new or worsening adverse event that began on or after the date of the first dose of study drug until the Day 17 study visit date + 2 (Day 19 if Day 17 visit missing).

Time frame: First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)

Population: The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (velpatasvir or placebo). Data were summarized by velpatasvir or placebo.

Arm	Measure	Value (NUMBER)
Placebo	Percentage of Participants Experiencing Treatment Emergent Adverse Events	17.6 percentage of participants
Velpatasvir 5 mg	Percentage of Participants Experiencing Treatment Emergent Adverse Events	25.0 percentage of participants
Velpatasvir 25 mg	Percentage of Participants Experiencing Treatment Emergent Adverse Events	26.7 percentage of participants
Velpatasvir 50 mg	Percentage of Participants Experiencing Treatment Emergent Adverse Events	8.3 percentage of participants
Velpatasvir 100 mg	Percentage of Participants Experiencing Treatment Emergent Adverse Events	37.5 percentage of participants
Velpatasvir 150 mg	Percentage of Participants Experiencing Treatment Emergent Adverse Events	29.0 percentage of participants

Primary

Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 abnormality grade from baseline at any postbaseline visit up to the Day 17 visit date + 2 days (or Day 19 if Day 17 visit was missing). The criteria used to grade laboratory results were as follows: Grade 1 (mild), Grade 2 (moderate), or Grade 3 (severe). Graded laboratory abnormalities were defined using the grading scheme defined in protocol (Gilead Sciences, Inc. Grading Scale for Severity of Adverse Events and Laboratory Abnormalities) for analysis purpose.

Time frame: First dose date up to Day 17 + 2 (Day 19 if Day 17 visit missing)

Population: Participants in the Safety Analysis Set were analyzed. Data were summarized by dose.

Arm	Measure	Group	Value (NUMBER)
Placebo	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	17.6 percentage of participants
Placebo	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	41.2 percentage of participants
Placebo	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	11.8 percentage of participants
Velpatasvir 5 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	0 percentage of participants
Velpatasvir 5 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	25.0 percentage of participants
Velpatasvir 5 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	0 percentage of participants
Velpatasvir 25 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	33.3 percentage of participants
Velpatasvir 25 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	40.0 percentage of participants
Velpatasvir 25 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	13.3 percentage of participants
Velpatasvir 50 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	8.3 percentage of participants
Velpatasvir 50 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	58.3 percentage of participants
Velpatasvir 50 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	16.7 percentage of participants
Velpatasvir 100 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	25.0 percentage of participants
Velpatasvir 100 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	62.5 percentage of participants
Velpatasvir 100 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	0 percentage of participants
Velpatasvir 150 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 1	33.3 percentage of participants
Velpatasvir 150 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 3	6.7 percentage of participants
Velpatasvir 150 mg	Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities	Grade 2	33.3 percentage of participants

Secondary

Absolute HCV RNA Level

Time frame: Baseline; Days 4, 5, 6, 7, 8, 10, and 17

Population: Participants in the Efficacy Analysis Set with available data were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Absolute HCV RNA Level	Day 7	6.527 log10 IU/mL	Standard Deviation 0.619
Placebo	Absolute HCV RNA Level	Day 17	6.503 log10 IU/mL	Standard Deviation 0.5432
Placebo	Absolute HCV RNA Level	Day 5	6.512 log10 IU/mL	Standard Deviation 0.5715
Placebo	Absolute HCV RNA Level	Day 8	6.555 log10 IU/mL	Standard Deviation 0.488
Placebo	Absolute HCV RNA Level	Baseline	6.523 log10 IU/mL	Standard Deviation 0.5173
Placebo	Absolute HCV RNA Level	Day 6	6.493 log10 IU/mL	Standard Deviation 0.5373
Placebo	Absolute HCV RNA Level	Day 4	6.518 log10 IU/mL	Standard Deviation 0.484
Placebo	Absolute HCV RNA Level	Day 10	6.659 log10 IU/mL	Standard Deviation 0.4583
Velpatasvir 5 mg	Absolute HCV RNA Level	Baseline	6.639 log10 IU/mL	Standard Deviation 0.3123
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 6	5.395 log10 IU/mL	Standard Deviation 0.6898
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 17	6.505 log10 IU/mL	Standard Deviation 0.5615
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 10	5.960 log10 IU/mL	Standard Deviation 0.6104
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 7	5.608 log10 IU/mL	Standard Deviation 0.6929
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 4	3.535 log10 IU/mL	Standard Deviation 0.7588
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 5	4.642 log10 IU/mL	Standard Deviation 0.9016
Velpatasvir 5 mg	Absolute HCV RNA Level	Day 8	5.699 log10 IU/mL	Standard Deviation 0.6305
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 5	2.922 log10 IU/mL	Standard Deviation 1.0852
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 4	2.823 log10 IU/mL	Standard Deviation 0.7866
Velpatasvir 25 mg	Absolute HCV RNA Level	Baseline	6.461 log10 IU/mL	Standard Deviation 0.6623
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 7	4.036 log10 IU/mL	Standard Deviation 1.1305
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 8	4.387 log10 IU/mL	Standard Deviation 1.1089
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 17	6.237 log10 IU/mL	Standard Deviation 0.6709
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 6	3.321 log10 IU/mL	Standard Deviation 1.3322
Velpatasvir 25 mg	Absolute HCV RNA Level	Day 10	5.156 log10 IU/mL	Standard Deviation 1.3456
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 17	5.468 log10 IU/mL	Standard Deviation 1.6269
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 10	4.986 log10 IU/mL	Standard Deviation 1.7558
Velpatasvir 50 mg	Absolute HCV RNA Level	Baseline	6.459 log10 IU/mL	Standard Deviation 0.5726
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 8	4.756 log10 IU/mL	Standard Deviation 1.9494
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 6	3.755 log10 IU/mL	Standard Deviation 1.9323
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 7	4.275 log10 IU/mL	Standard Deviation 1.9196
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 5	3.336 log10 IU/mL	Standard Deviation 1.8716
Velpatasvir 50 mg	Absolute HCV RNA Level	Day 4	3.121 log10 IU/mL	Standard Deviation 1.6969
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 8	4.678 log10 IU/mL	Standard Deviation 1.3233
Velpatasvir 100 mg	Absolute HCV RNA Level	Baseline	6.458 log10 IU/mL	Standard Deviation 0.4785
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 17	5.657 log10 IU/mL	Standard Deviation 1.0148
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 4	3.304 log10 IU/mL	Standard Deviation 1.2823
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 5	3.398 log10 IU/mL	Standard Deviation 1.3325
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 10	5.315 log10 IU/mL	Standard Deviation 1.513
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 6	3.745 log10 IU/mL	Standard Deviation 1.3213
Velpatasvir 100 mg	Absolute HCV RNA Level	Day 7	4.185 log10 IU/mL	Standard Deviation 1.4107
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 5	2.699 log10 IU/mL	Standard Deviation 1.0083
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 6	3.104 log10 IU/mL	Standard Deviation 1.2373
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 4	2.687 log10 IU/mL	Standard Deviation 0.8776
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 8	3.791 log10 IU/mL	Standard Deviation 1.5984
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 17	5.455 log10 IU/mL	Standard Deviation 1.2889
Velpatasvir 150 mg	Absolute HCV RNA Level	Baseline	6.335 log10 IU/mL	Standard Deviation 0.571
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 10	4.319 log10 IU/mL	Standard Deviation 1.6357
Velpatasvir 150 mg	Absolute HCV RNA Level	Day 7	3.862 log10 IU/mL	Standard Deviation 1.4141
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Baseline	6.379 log10 IU/mL	Standard Deviation 0.4187
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 7	2.217 log10 IU/mL	Standard Deviation 0.5807
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 5	2.466 log10 IU/mL	Standard Deviation 0.3511
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 6	2.400 log10 IU/mL	Standard Deviation 0.3365
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 10	3.074 log10 IU/mL	Standard Deviation 0.866
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 4	2.574 log10 IU/mL	Standard Deviation 0.3526
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 17	4.890 log10 IU/mL	Standard Deviation 1.5438
Velpatasvir 150 mg (GT 1b)	Absolute HCV RNA Level	Day 8	2.396 log10 IU/mL	Standard Deviation 0.6092
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 4	2.708 log10 IU/mL	Standard Deviation 0.5823
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Baseline	6.753 log10 IU/mL	Standard Deviation 0.5857
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 5	2.681 log10 IU/mL	Standard Deviation 0.3893
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 6	2.644 log10 IU/mL	Standard Deviation 0.6568
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 7	2.903 log10 IU/mL	Standard Deviation 0.7639
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 8	3.194 log10 IU/mL	Standard Deviation 0.8402
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 10	3.834 log10 IU/mL	Standard Deviation 1.171
Velpatasvir 150 mg (GT 2)	Absolute HCV RNA Level	Day 17	5.867 log10 IU/mL	Standard Deviation 1.5443
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 7	4.361 log10 IU/mL	Standard Deviation 1.413
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 8	4.922 log10 IU/mL	Standard Deviation 1.3395
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 6	3.753 log10 IU/mL	Standard Deviation 1.6214
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 5	3.329 log10 IU/mL	Standard Deviation 1.8305
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 10	5.103 log10 IU/mL	Standard Deviation 1.1273
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 4	3.151 log10 IU/mL	Standard Deviation 2.009
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Baseline	6.150 log10 IU/mL	Standard Deviation 1.0108
Velpatasvir 25 mg (GT 3)	Absolute HCV RNA Level	Day 17	5.275 log10 IU/mL	Standard Deviation 1.1421
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 7	4.498 log10 IU/mL	Standard Deviation 1.9226
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 10	5.190 log10 IU/mL	Standard Deviation 2.0061
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 5	4.110 log10 IU/mL	Standard Deviation 1.8964
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 4	3.858 log10 IU/mL	Standard Deviation 1.912
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 6	4.503 log10 IU/mL	Standard Deviation 1.9383
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Baseline	6.240 log10 IU/mL	Standard Deviation 0.5796
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 17	6.007 log10 IU/mL	Standard Deviation 0.9524
Velpatasvir 50 mg (GT 3)	Absolute HCV RNA Level	Day 8	4.698 log10 IU/mL	Standard Deviation 1.6047
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 4	3.484 log10 IU/mL	Standard Deviation 0.6784
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 7	4.938 log10 IU/mL	Standard Deviation 1.4707
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 5	4.059 log10 IU/mL	Standard Deviation 1.0186
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 17	6.093 log10 IU/mL	Standard Deviation 0.6451
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 10	5.120 log10 IU/mL	Standard Deviation 0.614
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Baseline	6.318 log10 IU/mL	Standard Deviation 0.8151
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 6	4.450 log10 IU/mL	Standard Deviation 1.1943
Velpatasvir 150 mg (GT 3)	Absolute HCV RNA Level	Day 8	5.256 log10 IU/mL	Standard Deviation 1.3141
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 5	2.907 log10 IU/mL	Standard Deviation 0.785
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 6	3.491 log10 IU/mL	Standard Deviation 0.8264
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 8	4.256 log10 IU/mL	Standard Deviation 1.3887
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 4	2.465 log10 IU/mL	Standard Deviation 0.8425
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 17	5.383 log10 IU/mL	Standard Deviation 0.8259
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 10	5.240 log10 IU/mL	Standard Deviation 1.1278
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Day 7	3.842 log10 IU/mL	Standard Deviation 1.2488
Velpatasvir 150 mg (GT 4)	Absolute HCV RNA Level	Baseline	5.734 log10 IU/mL	Standard Deviation 0.2345

Secondary

Number of Participants Achieving Reductions From Baseline in HCV RNA

Categorical declines from baseline were summarized by the number of participants with a \< 1, ≥ 1 to \< 2, ≥ 2 to \< 3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline by treatment (velpatasvir dose/HCV genotype) and placebo at each collection time point through Day 17.

Time frame: Baseline; Days 4, 5, 6, 7, 8, 10, and 17

Population: Participants in the Efficacy Analysis Set were analyzed.

Arm	Measure	Group	Category	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	15 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	15 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	15 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	2 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	2 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	16 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	1 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	16 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	15 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	2 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	2 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	17 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	1 Participants
Placebo	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 5 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	8 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 50 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 100 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	6 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	1 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 150 mg	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	2 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	6 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	8 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	6 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	7 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	5 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	1 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	4 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	3 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	6 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	< 1 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥1 and <2 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 8	≥1 and <2 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	≥2 and <3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 7	< 1 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥2 and <3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 4	≥3 log10 IU/mL decrease in HCV RNA	1 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 5	Missing HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 6	≥3 log10 IU/mL decrease in HCV RNA	0 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 17	< 1 log10 IU/mL decrease in HCV RNA	2 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants Achieving Reductions From Baseline in HCV RNA	Day 10	≥3 log10 IU/mL decrease in HCV RNA	0 Participants

Secondary

Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected

The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 25 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay.

Time frame: Days 4, 5, 6, 7, and 8

Population: Participants in the Efficacy Analysis Set were analyzed. Data were summarized by treatment (velpatasvir dose/HCV genotype) and placebo.

Arm	Measure	Group	Value (NUMBER)
Placebo	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Placebo	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Placebo	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Placebo	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Placebo	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 5 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 5 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 5 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 5 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 5 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 25 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	1 participants
Velpatasvir 25 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	1 participants
Velpatasvir 25 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 25 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 25 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 50 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	1 participants
Velpatasvir 50 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	2 participants
Velpatasvir 50 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 50 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	1 participants
Velpatasvir 50 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 100 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 100 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 100 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 100 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 100 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 150 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	1 participants
Velpatasvir 150 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	1 participants
Velpatasvir 150 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 150 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	1 participants
Velpatasvir 150 mg	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	1 participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 1b)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 2)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 2)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 2)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	1 participants
Velpatasvir 150 mg (GT 2)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 2)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 25 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 25 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 25 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 25 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	1 participants
Velpatasvir 25 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	1 participants
Velpatasvir 50 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 50 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 50 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 50 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 50 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 3)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 4)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 7 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 4)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 5 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 4)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 6 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 4)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 4 < LLOQ detected	0 participants
Velpatasvir 150 mg (GT 4)	Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected	Day 8 < LLOQ detected	0 participants

Secondary

Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints

The full-length NS5A coding region was analyzed pretreatment (baseline) by deep sequencing using MiSeq for all 70 participants who received velpatasvir and for 8 of 17 participants who received placebo prior to and up to 2 weeks (Day 17) after dosing with velpatasvir. Participants were categorized by velpatasvir dose/HCV genotype and presence or absence of NS5A RAVs.

Time frame: First dose date up to Day 17

Population: Participants in the efficacy analysis set who were sequenced at pre-treatment or post baseline treatment were analyzed.

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Placebo	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	2 Participants
Placebo	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Placebo	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	0 Participants
Placebo	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 5 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	0 Participants
Velpatasvir 5 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	4 Participants
Velpatasvir 5 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	4 Participants
Velpatasvir 5 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	4 Participants
Velpatasvir 25 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 25 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Velpatasvir 25 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	8 Participants
Velpatasvir 25 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	7 Participants
Velpatasvir 50 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 50 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	6 Participants
Velpatasvir 50 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	3 Participants
Velpatasvir 50 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	7 Participants
Velpatasvir 100 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	3 Participants
Velpatasvir 100 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	8 Participants
Velpatasvir 100 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	8 Participants
Velpatasvir 100 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 150 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	7 Participants
Velpatasvir 150 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Velpatasvir 150 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	6 Participants
Velpatasvir 150 mg	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	6 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	6 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	1 Participants
Velpatasvir 150 mg (GT 1b)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	6 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	4 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	8 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	7 Participants
Velpatasvir 150 mg (GT 2)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	8 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	6 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	6 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Velpatasvir 25 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	7 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	4 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	4 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	1 Participants
Velpatasvir 50 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	4 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	6 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	6 Participants
Velpatasvir 150 mg (GT 3)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	6 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced pretreatment	2 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants sequenced at postbaseline	2 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at pretreatment	2 Participants
Velpatasvir 150 mg (GT 4)	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints	Number of participants with RAVs at postbaseline	2 Participants

Secondary

Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf

AUCinf is defined as the concentration of drug extrapolated to infinite time.

Time frame: 0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1

Population: The PK analysis set included all randomized and treated participants who have evaluable PK profiles for velpatasvir.

Arm	Measure	Value (MEAN)	Dispersion
Placebo	Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	113.8 h*ng/mL	Standard Deviation 71.61
Velpatasvir 5 mg	Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	857.9 h*ng/mL	Standard Deviation 612.23
Velpatasvir 25 mg	Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	2054.3 h*ng/mL	Standard Deviation 806.69
Velpatasvir 50 mg	Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	2727.3 h*ng/mL	Standard Deviation 1619.74
Velpatasvir 100 mg	Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf	4546.6 h*ng/mL	Standard Deviation 1757.1

Secondary

PK Parameter of Velpatasvir: AUCtau

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame: 0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3

Population: Participants in the PK Analysis Set were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Placebo	PK Parameter of Velpatasvir: AUCtau	86.4 h*ng/mL	Standard Deviation 14.32
Velpatasvir 5 mg	PK Parameter of Velpatasvir: AUCtau	857.5 h*ng/mL	Standard Deviation 467.74
Velpatasvir 25 mg	PK Parameter of Velpatasvir: AUCtau	1950.5 h*ng/mL	Standard Deviation 486.87
Velpatasvir 50 mg	PK Parameter of Velpatasvir: AUCtau	2745.3 h*ng/mL	Standard Deviation 1480.47
Velpatasvir 100 mg	PK Parameter of Velpatasvir: AUCtau	5003.0 h*ng/mL	Standard Deviation 2371.91

Secondary

PK Parameter of Velpatasvir: CL/F

CL/F is defined as the apparent oral clearance following administration of the drug.

Time frame: 0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose

Population: Participants in the PK Analysis Set were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	PK Parameter of Velpatasvir: CL/F	Day 1	61312.2 mL/hr	Standard Deviation 42726.76
Placebo	PK Parameter of Velpatasvir: CL/F	Day 3	59173.6 mL/hr	Standard Deviation 10490.08
Velpatasvir 5 mg	PK Parameter of Velpatasvir: CL/F	Day 1	37170.7 mL/hr	Standard Deviation 16570.51
Velpatasvir 5 mg	PK Parameter of Velpatasvir: CL/F	Day 3	34,820.1 mL/hr	Standard Deviation 13217.45
Velpatasvir 25 mg	PK Parameter of Velpatasvir: CL/F	Day 1	27930.6 mL/hr	Standard Deviation 10689.18
Velpatasvir 25 mg	PK Parameter of Velpatasvir: CL/F	Day 3	27,263.0 mL/hr	Standard Deviation 7367.47
Velpatasvir 50 mg	PK Parameter of Velpatasvir: CL/F	Day 3	53,194.3 mL/hr	Standard Deviation 39618.97
Velpatasvir 50 mg	PK Parameter of Velpatasvir: CL/F	Day 1	49237.5 mL/hr	Standard Deviation 25550.98
Velpatasvir 100 mg	PK Parameter of Velpatasvir: CL/F	Day 1	38011.7 mL/hr	Standard Deviation 14392.55
Velpatasvir 100 mg	PK Parameter of Velpatasvir: CL/F	Day 3	37,362.8 mL/hr	Standard Deviation 18382.06

Secondary

PK Parameter of Velpatasvir: Cmax

Cmax is defined as the maximum observed plasma concentration of drug.

Time frame: 0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 1 for single dose and Day 3 for multiple dose.

Population: Participants in the PK Analysis Set were analyzed.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	PK Parameter of Velpatasvir: Cmax	Day 1 (Single-Dose)	20.1 ng/mL	Standard Deviation 14.62
Placebo	PK Parameter of Velpatasvir: Cmax	Day 3 (Multiple-Dose)	16.2 ng/mL	Standard Deviation 2.34
Velpatasvir 5 mg	PK Parameter of Velpatasvir: Cmax	Day 3 (Multiple-Dose)	122.9 ng/mL	Standard Deviation 61.38
Velpatasvir 5 mg	PK Parameter of Velpatasvir: Cmax	Day 1 (Single-Dose)	110.8 ng/mL	Standard Deviation 55.97
Velpatasvir 25 mg	PK Parameter of Velpatasvir: Cmax	Day 3 (Multiple-Dose)	292.4 ng/mL	Standard Deviation 88.77
Velpatasvir 25 mg	PK Parameter of Velpatasvir: Cmax	Day 1 (Single-Dose)	272.3 ng/mL	Standard Deviation 95.46
Velpatasvir 50 mg	PK Parameter of Velpatasvir: Cmax	Day 1 (Single-Dose)	372.8 ng/mL	Standard Deviation 222.74
Velpatasvir 50 mg	PK Parameter of Velpatasvir: Cmax	Day 3 (Multiple-Dose)	413.9 ng/mL	Standard Deviation 243.66
Velpatasvir 100 mg	PK Parameter of Velpatasvir: Cmax	Day 3 (Multiple-Dose)	690.1 ng/mL	Standard Deviation 307.04
Velpatasvir 100 mg	PK Parameter of Velpatasvir: Cmax	Day 1 (Single-Dose)	583.3 ng/mL	Standard Deviation 257.9

Secondary

PK Parameter of Velpatasvir: Ctau

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame: 0 (predose), 0.5, 1, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, and 24 hours postdose at Day 3

Population: Participants in the PK Analysis Set were analyzed.

Arm	Measure	Value (MEAN)	Dispersion
Placebo	PK Parameter of Velpatasvir: Ctau	0.6 ng/mL	Standard Deviation 0.7
Velpatasvir 5 mg	PK Parameter of Velpatasvir: Ctau	10.8 ng/mL	Standard Deviation 8.5
Velpatasvir 25 mg	PK Parameter of Velpatasvir: Ctau	22.4 ng/mL	Standard Deviation 4.66
Velpatasvir 50 mg	PK Parameter of Velpatasvir: Ctau	30.8 ng/mL	Standard Deviation 15.03
Velpatasvir 100 mg	PK Parameter of Velpatasvir: Ctau	60.6 ng/mL	Standard Deviation 33.24

Secondary

Plasma HCV RNA Levels by Treatment and IL28B Genotype

Time frame: Days 4, 5, 6, 7, 8, 10, and 17

Population: Participants in the Efficacy Analysis Set with available data were analyzed. Data are were summarized by treatment (velpatasvir dose/HCV genotype and placebo) and IL28B genotype (CC and non-CC). Due to the small number of participants in each treatment group, no conclusions can be made on the effect of IL28B genotype on HCV RNA decline.

Arm	Measure	Group	Value (MEAN)	Dispersion
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	6.817 log10 IU/mL	Standard Deviation 0.3336
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	6.563 log10 IU/mL	Standard Deviation 0.3311
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	6.595 log10 IU/mL	Standard Deviation 0.3266
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	6.643 log10 IU/mL	Standard Deviation 0.4611
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.601 log10 IU/mL	Standard Deviation 0.3466
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	6.473 log10 IU/mL	Standard Deviation 0.4869
Placebo	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	6.604 log10 IU/mL	Standard Deviation 0.4842
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.713 log10 IU/mL	Standard Deviation 0.6714
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.410 log10 IU/mL	Standard Deviation 0.4007
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	5.612 log10 IU/mL	Standard Deviation 0.4912
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	6.171 log10 IU/mL	Standard Deviation 0.8102
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	4.578 log10 IU/mL	Standard Deviation 0.6202
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	5.744 log10 IU/mL	Standard Deviation 0.7194
Velpatasvir 5 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	5.388 log10 IU/mL	Standard Deviation 0.5909
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.875 log10 IU/mL	Standard Deviation 0.5026
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.740 log10 IU/mL	Standard Deviation 1.238
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	4.369 log10 IU/mL	Standard Deviation 0.3684
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.147 log10 IU/mL	Standard Deviation 1.0166
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.581 log10 IU/mL	Standard Deviation 1.0972
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.603 log10 IU/mL	Standard Deviation 0.5255
Velpatasvir 25 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.637 log10 IU/mL	Standard Deviation 0.7489
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	2.949 log10 IU/mL	—
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	1.762 log10 IU/mL	Standard Deviation 0.5394
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	3.488 log10 IU/mL	Standard Deviation 1.1964
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	1.748 log10 IU/mL	Standard Deviation 0.011
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.134 log10 IU/mL	Standard Deviation 0.3192
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.053 log10 IU/mL	Standard Deviation 1.1852
Velpatasvir 50 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	2.988 log10 IU/mL	Standard Deviation 0.731
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	4.572 log10 IU/mL	Standard Deviation 0.1838
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.891 log10 IU/mL	Standard Deviation 0.4237
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.138 log10 IU/mL	Standard Deviation 0.5754
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.867 log10 IU/mL	Standard Deviation 0.3347
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.390 log10 IU/mL	Standard Deviation 0.1908
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.996 log10 IU/mL	Standard Deviation 0.4644
Velpatasvir 100 mg	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	4.059 log10 IU/mL	Standard Deviation 0.0027
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.953 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.539 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.605 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	3.948 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.801 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.441 log10 IU/mL	—
Velpatasvir 150 mg (GT 1b)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.312 log10 IU/mL	—
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.689 log10 IU/mL	Standard Deviation 0.5473
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.668 log10 IU/mL	Standard Deviation 0.7974
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.758 log10 IU/mL	Standard Deviation 0.3416
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	3.438 log10 IU/mL	Standard Deviation 1.2872
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	2.913 log10 IU/mL	Standard Deviation 1.0913
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.127 log10 IU/mL	Standard Deviation 1.8225
Velpatasvir 150 mg (GT 2)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	2.684 log10 IU/mL	Standard Deviation 1.03
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.553 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.117 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.976 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.813 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.061 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.744 log10 IU/mL	—
Velpatasvir 25 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	4.196 log10 IU/mL	—
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	4.304 log10 IU/mL	Standard Deviation 2.0716
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	5.123 log10 IU/mL	Standard Deviation 1.6669
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.881 log10 IU/mL	Standard Deviation 1.3108
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.724 log10 IU/mL	Standard Deviation 2.0787
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	5.035 log10 IU/mL	Standard Deviation 1.9842
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	4.620 log10 IU/mL	Standard Deviation 1.9568
Velpatasvir 50 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	5.038 log10 IU/mL	Standard Deviation 1.9476
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	4.754 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.621 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.742 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.653 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.114 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.713 log10 IU/mL	—
Velpatasvir 150 mg (GT 3)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.590 log10 IU/mL	—
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	6.549 log10 IU/mL	Standard Deviation 0.5057
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	6.504 log10 IU/mL	Standard Deviation 0.7748
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.444 log10 IU/mL	Standard Deviation 0.644
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	6.503 log10 IU/mL	Standard Deviation 0.5202
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	6.426 log10 IU/mL	Standard Deviation 0.6525
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	6.450 log10 IU/mL	Standard Deviation 0.6437
Placebo (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	6.580 log10 IU/mL	Standard Deviation 0.5065
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	5.604 log10 IU/mL	Standard Deviation 1.0949
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.660 log10 IU/mL	Standard Deviation 1.2265
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	4.705 log10 IU/mL	Standard Deviation 1.4275
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	5.403 log10 IU/mL	Standard Deviation 1.0383
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	5.653 log10 IU/mL	Standard Deviation 0.8166
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.750 log10 IU/mL	Standard Deviation 0.5333
Velpatasvir 5 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.297 log10 IU/mL	Standard Deviation 0.5676
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.669 log10 IU/mL	Standard Deviation 1.391
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.292 log10 IU/mL	Standard Deviation 0.511
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	4.276 log10 IU/mL	Standard Deviation 1.3284
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.955 log10 IU/mL	Standard Deviation 0.9418
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.127 log10 IU/mL	Standard Deviation 1.1484
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.629 log10 IU/mL	Standard Deviation 1.5354
Velpatasvir 25 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.694 log10 IU/mL	Standard Deviation 1.3082
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.865 log10 IU/mL	Standard Deviation 1.8868
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	4.295 log10 IU/mL	Standard Deviation 1.951
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.574 log10 IU/mL	Standard Deviation 1.7284
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.888 log10 IU/mL	Standard Deviation 1.3019
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.485 log10 IU/mL	Standard Deviation 1.6832
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	4.704 log10 IU/mL	Standard Deviation 2.0419
Velpatasvir 50 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	5.324 log10 IU/mL	Standard Deviation 1.8687
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.532 log10 IU/mL	Standard Deviation 1.535
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.442 log10 IU/mL	Standard Deviation 1.4747
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.949 log10 IU/mL	Standard Deviation 1.4416
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.733 log10 IU/mL	Standard Deviation 1.5375
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.019 log10 IU/mL	Standard Deviation 0.8985
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.947 log10 IU/mL	Standard Deviation 1.4771
Velpatasvir 100 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	4.449 log10 IU/mL	Standard Deviation 1.5628
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.687 log10 IU/mL	Standard Deviation 0.8776
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.104 log10 IU/mL	Standard Deviation 1.2373
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.791 log10 IU/mL	Standard Deviation 1.5984
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.699 log10 IU/mL	Standard Deviation 1.0083
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	4.319 log10 IU/mL	Standard Deviation 1.6357
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.455 log10 IU/mL	Standard Deviation 1.2889
Velpatasvir 150 mg (GT 1a) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.862 log10 IU/mL	Standard Deviation 1.4141
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	4.546 log10 IU/mL	Standard Deviation 1.3663
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	2.222 log10 IU/mL	Standard Deviation 0.4366
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	2.034 log10 IU/mL	Standard Deviation 0.3534
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.579 log10 IU/mL	Standard Deviation 0.3859
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.334 log10 IU/mL	Standard Deviation 0.3139
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.443 log10 IU/mL	Standard Deviation 0.3787
Velpatasvir 150 mg (GT 1b) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	2.928 log10 IU/mL	Standard Deviation 0.8495
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.034 log10 IU/mL	Standard Deviation 0.6583
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	4.073 log10 IU/mL	Standard Deviation 1.1757
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.362 log10 IU/mL	Standard Deviation 0.7384
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.673 log10 IU/mL	Standard Deviation 0.2813
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.311 log10 IU/mL	Standard Deviation 1.3623
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.678 log10 IU/mL	Standard Deviation 0.7295
Velpatasvir 150 mg (GT 2) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.629 log10 IU/mL	Standard Deviation 0.6604
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.996 log10 IU/mL	Standard Deviation 1.4838
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	3.372 log10 IU/mL	Standard Deviation 2.0433
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	4.981 log10 IU/mL	Standard Deviation 0.9912
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.111 log10 IU/mL	Standard Deviation 1.2601
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.741 log10 IU/mL	Standard Deviation 1.8125
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	4.394 log10 IU/mL	Standard Deviation 1.5772
Velpatasvir 25 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.186 log10 IU/mL	Standard Deviation 2.2441
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	2.877 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.577 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	2.907 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	3.585 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.521 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	6.260 log10 IU/mL	—
Velpatasvir 50 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	3.423 log10 IU/mL	—
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.987 log10 IU/mL	Standard Deviation 0.6606
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	4.609 log10 IU/mL	Standard Deviation 1.262
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	4.123 log10 IU/mL	Standard Deviation 1.1255
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	5.485 log10 IU/mL	Standard Deviation 1.3293
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.193 log10 IU/mL	Standard Deviation 0.6566
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	3.463 log10 IU/mL	Standard Deviation 0.7562
Velpatasvir 150 mg (GT 3) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	5.183 log10 IU/mL	Standard Deviation 1.5012
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 8	4.256 log10 IU/mL	Standard Deviation 1.3887
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 4	2.465 log10 IU/mL	Standard Deviation 0.8425
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 6	3.491 log10 IU/mL	Standard Deviation 0.8264
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 5	2.907 log10 IU/mL	Standard Deviation 0.785
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 17	5.383 log10 IU/mL	Standard Deviation 0.8259
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 7	3.842 log10 IU/mL	Standard Deviation 1.2488
Velpatasvir 150 mg (GT 4) (IL28B Genotype Non-CC)	Plasma HCV RNA Levels by Treatment and IL28B Genotype	Day 10	5.240 log10 IU/mL	Standard Deviation 1.1278

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection

Conditions

Keywords

Brief summary

Related papers

Interventions

Sponsors

Study design

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Recruitment details

Pre-assignment details

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

Antiviral Activity of Velpatasvir as Measured by Change in Plasma HCV RNA From Baseline

Percentage of Participants Experiencing Treatment Emergent Adverse Events

Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

Absolute HCV RNA Level

Number of Participants Achieving Reductions From Baseline in HCV RNA

Number of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected

Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Associated Variants (RAVs) at Pretreatment or Postbaseline Timepoints

Pharmacokinetic (PK) Parameter of Velpatasvir: AUCinf

PK Parameter of Velpatasvir: AUCtau

PK Parameter of Velpatasvir: CL/F

PK Parameter of Velpatasvir: Cmax

PK Parameter of Velpatasvir: Ctau

Plasma HCV RNA Levels by Treatment and IL28B Genotype